Media coverage about Heron Therapeutics (NASDAQ:HRTX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Heron Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.9778606844926 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the headlines that may have impacted Accern’s analysis:

Shares of Heron Therapeutics (HRTX) opened at $15.55 on Monday. Heron Therapeutics has a fifty-two week low of $12.21 and a fifty-two week high of $18.40. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.10. The business had revenue of $8.57 million for the quarter, compared to analysts’ expectations of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. equities research analysts forecast that Heron Therapeutics will post -3.41 EPS for the current year.

Several research analysts recently commented on the stock. Oppenheimer reaffirmed a “buy” rating and issued a $27.00 target price on shares of Heron Therapeutics in a research note on Friday, November 10th. Northland Securities assumed coverage on shares of Heron Therapeutics in a research note on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 target price on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $31.00 target price on shares of Heron Therapeutics in a research note on Thursday, November 2nd. Mizuho assumed coverage on shares of Heron Therapeutics in a research note on Tuesday, September 26th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Sunday, November 12th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Heron Therapeutics has a consensus rating of “Buy” and an average target price of $28.73.

TRADEMARK VIOLATION WARNING: “Heron Therapeutics (HRTX) Given News Impact Score of 0.17” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/heron-therapeutics-hrtx-given-news-impact-score-of-0-17/1770510.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Insider Buying and Selling by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.